Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
XORTX Therapeutics Inc
V.XRTX
Alternate Symbol(s):
XRTX
Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance...
its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:XRTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(4)
•••
MamaZinka
X
View Profile
View Bullboard History
Post by
MamaZinka
on Feb 21, 2024 1:07am
Good OVERVIEW..on Xortx ... XRTX
XRTX .. currently trades at Cash break up value ... zero value for there 2 FDA level 2 drugs.. and one is pre - Clinicals .. Management with proven track record of creating shareholder value... very
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Feb 15, 2024 8:26am
XRTX....NR this a.m re: financing...On watch still ; )
ORIGINAL: XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units 2024-02-15 04:00 ET - News Release NOT FOR
...more
Lahontan Gold Announces Filing of Santa Fe Technical Report
posted Nov 29, 2024 9:00am by
Lahontan Gold Corp.
-
|
Lahontan Gold is pleased to announce that the Company has filed on SEDAR+ an independent Technical Report and updated Mineral Resource Estimate ("MRE") titled "Santa Fe Project Technical Report," effective October 9, 2024, and dated November 27, 2024, for Lahontan's Santa Fe Mine gold and silver project, Santa Fe District, Mineral County, Nevada. ...read more
(9)
•••
averagepennies
X
View Profile
View Bullboard History
Post by
averagepennies
on Feb 02, 2024 9:22am
XORTX Files an Amended and Restated Prospectus Supplement
CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 01, 2024 8:46pm
New Press Release - XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESCALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 29, 2024 10:32am
XRTX....Interlisted in Cad & U.S
On watch list still
(9)
•••
averagepennies
X
View Profile
View Bullboard History
Post by
averagepennies
on Jan 16, 2024 8:19am
XORTX Announces $2 Million Public Offering
CALGARY, Alberta, Jan. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company
...more
(2182)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Jan 14, 2024 11:11pm
$2 million financing
$3 per unit ( 1 sh + 1 wrt)
(9)
•••
averagepennies
X
View Profile
View Bullboard History
Post by
averagepennies
on Jan 05, 2024 9:55am
XORTX Submits a New Patent for the Treatment of Chronic Kidn
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical
...more
(106)
•••
Peggy123
X
View Profile
View Bullboard History
Comment by
Peggy123
on Jan 04, 2024 3:50pm
RE:unbelievable up .80 cents to .08 cents. penny flippers
unbelievable up 1.11 at one point
(106)
•••
Peggy123
X
View Profile
View Bullboard History
Post by
Peggy123
on Jan 03, 2024 2:59pm
unbelievable up .80 cents to .08 cents. penny flippers
grrrrrr
(3217)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Jan 03, 2024 12:06pm
XORTX Submits a New Patent for the Treatment
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical
...more
(106)
•••
Peggy123
X
View Profile
View Bullboard History
Post by
Peggy123
on Dec 11, 2023 1:43pm
Got filled
2700 @ 7.10 Papi
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 30, 2023 8:30am
XRTX....XORTX Announces US ATM Offering
Read the previous post for details On watch
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 30, 2023 7:30am
New Press Release - XORTX Announces US ATM Offering
CALGARY, Alberta, Nov. 30, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 29, 2023 7:00am
New Press Release - XORTX Meets Nasdaq Continued Listing Requirements
CALGARY, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >